These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28009939)

  • 1. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
    Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
    Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of an α
    Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
    Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ; Cho ST; Kuo HC; Chou EC; Hsu YC; Lee KS; Hadi F; Song Y; Sumarsono B
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence.
    Özkidik M; Coşkun A; Asutay MK; Bahçeci T; Hamidi N
    Int Braz J Urol; 2019; 45(4):782-789. PubMed ID: 31136113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
    Fogaing C; Mossa AH; Campeau L
    Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
    Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
    J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.
    Zhao L; Wu F; Wang J; Wang Y; Peng W; Chen Y
    World J Urol; 2024 Jun; 42(1):370. PubMed ID: 38847900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
    Mullen GR; Kaplan SA
    Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder medication: Persistence, drug switching, and reinitiation.
    Soda T; Tashiro Y; Koike S; Ikeuchi R; Okada T
    Neurourol Urodyn; 2020 Nov; 39(8):2527-2534. PubMed ID: 32985716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
    Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
    Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
    Mandpe P; Prabhakar B; Shende P
    Curr Drug Metab; 2020; 21(2):79-88. PubMed ID: 32334500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
    Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
    Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
    Takahashi S; Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials.
    Wu Y; Li G; Zhou H; Wu A; Tan G; Huang S; Chen G; Chen X; Li Z
    Urol Int; 2024; 108(2):118-127. PubMed ID: 38185112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.